Reference Center for Oncohematological Diseases
The Reference Center for Oncohematological Diseases is the largest oncohematological diagnostic, treatment, training, and research center for rare blood diseases in Lithuania. The center provides a wide range of outpatient and inpatient services: consultations of hematologists, cardiologists, nephrologists, rheumatologists, gastroenterologists, dermatologists, neurologists, dieticians. The center uses the most advanced diagnostic and treatment technologies: laboratory, pathological, radiological, instrumental, molecular diagnostics, medical treatment, chemotherapy, and psychological assistance to patients.
This center is a structural unit of the Hematology, Oncology and Transfusion Medicine Center, Vilnius University Hospital Santaros Klinikos. Hematology, Oncology and Transfusion Medicine Center is the largest bone marrow transplantation center in the Baltic States and one of the largest in Europe.
The Reference Center for Oncohematological Diseases prioritizes the development of biomedical research that leads to medical innovations and treatment based on the latest technologies.
The center organizes and develops epidemiological studies of treatment outcomes and continuously improves treatment protocols based on the principles of evidence-based medicine. The doctors of the center participate in international conferences, regularly renew their knowledge and skills, and present research conducted in the center.
A unique monitoring system that collects data on newly diagnosed cases has been developed in the center. It tracks the course of the disease and evaluates the effectiveness of treatment. The data is analyzed and constantly updated.
The Reference Center for Oncohematological Diseases received the highest rating in the provision of healthcare to patients with rare blood diseases during an international audit in 2018. This proves that the qualifications of the hematologists and the entire medical team meet the high European standards and that cooperation with other European countries and participation in expert networks provides better diagnostic and treatment opportunities for rare diseases.
